Hereditary Cancer Panel denied as non-formulary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for hereditary cancer panel are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Hereditary Cancer Panel Testing as Non-Formulary

Hereditary cancer panels are laboratory-based genetic tests, not pharmaceutical products, but UnitedHealthcare manages them through a benefit-management framework that can resemble a formulary structure. A non-formulary denial typically means UHC either has a preferred genetic testing vendor or laboratory network under contract, or has categorized the specific panel ordered as outside its covered test menu. The denial is not a clinical judgment — it is an administrative benefit determination.

## Why This Denial Is Appealable

Non-formulary denials are among the most successfully overturned categories on appeal. If no in-network laboratory can perform an equivalent clinically validated panel, or if the specific panel ordered is the only one appropriate for the patient's clinical indication, you have a strong medical-necessity exception argument. UHC's own plan documents typically allow exceptions when no covered alternative exists or when the covered alternative would be clinically inferior for the patient's specific situation.

## Your Federal Appeal Rights

• Internal appeal: File a Level 1 internal appeal citing both the non-formulary classification and a concurrent medical-necessity exception request. ERISA §503 (for employer-sponsored plans) requires a full-and-fair review.
• External review: Under ACA §2719, if your internal appeal is denied, you may escalate to an independent external review. The standard external-review window is approximately four months from the final adverse determination. Expedited review is available if clinical urgency exists.

## Concrete Appeal Steps and Timeline

1. Confirm in writing which specific laboratory or panel UHC considers in-network or preferred. 2. Have the ordering clinician document why the specific test ordered is clinically necessary and whether the preferred alternative is adequate for this patient's genetic risk profile. 3. Submit a dual-track appeal: (a) non-formulary exception request under the plan's exception process, and (b) internal medical-necessity appeal. 4. If both are denied, file for external IRO review within the window on the denial notice.

## Documentation to Gather

• Test specificity rationale: A letter from the ordering clinician or genetic counselor explaining why the specific panel (number of genes, analytic methodology) is clinically required rather than a narrower preferred alternative.
• In-network adequacy gap: Evidence that no in-network or preferred laboratory offers a clinically equivalent panel for the patient's indication.
• Personal and family history: Multi-generational cancer history with detail sufficient to demonstrate the scope of testing required.
• Diagnosis and risk documentation: Clinical notes establishing the indication and anticipated management changes based on results.

## Criteria-Mapping Structure

Locate UHC's exception criteria for non-formulary or out-of-network laboratory tests in the plan's Evidence of Coverage document. Map each exception criterion to a specific chart fact, clinician statement, or documented gap in the preferred vendor's test menu. Presenting this side-by-side comparison greatly reduces the chance of a summary re-denial.